# Dantrolene

## Dantrolene inj 20mg (專案進口)

| TAH Drug Code      | [IDAN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDAN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of malignant hyperthermia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Malignant hyperthermia: (FDA dosage) Minimum 1 mg/kg IV push; if physiologic and metabolic abnormalities continue, administer additional IV boluses to a MAX cumulative dose of 10 mg/kg; if abnormalities reappear, repeat dosing starting with 1 mg/kg IV push. (Guideline dosage) Initially, give 2-3 mg/kg IV push, then 1 mg/kg every 5 minutes as needed with active cooling until CO2 levels are <6 kPa, normal ventilation, and core temperature is <38.5°C. Additional doses may be required for rebound increases in CO2 and temperature, typically within 14 hours of initial control. If rebound occurs within 6 hours, use 1 mg/kg; if >6 hours since the last dose, administer 2-3 mg/kg. After a cumulative dose of 10 mg/kg, reevaluate the diagnosis; if malignant hyperthermia is still likely, continue dantrolene administration. Obese patients: Use actual body weight for initial dose calculation Malignant hyperthermia, Post-crisis follow-up: Individualize dose starting with 1 mg/kg IV or more as the clinical situation dictates. Malignant hyperthermia; Prophylaxis: 2.5 mg/kg IVD over 1 hour, starting approximately 1.25 hours before anesthesia. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Hypersensitivity to Dantrolene.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common: Flushing (27%), Diarrhea, Nausea (10%), Somnolence (17%), Fatigue, Malaise Serious: Heart failure, Tachycardia (3%), Dysphagia (10%), Gastrointestinal hemorrhage, Aplastic anemia, Leukopenia, Small lymphocytic lymphoma, Thrombocytopenia, Anaphylaxis, Muscle weakness (3-21.7%), Decreased vital capacity, inspiratory, Dyspnea, Muscle weakness, respiratory                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | No (Limited) Human Data – No Relevant Animal Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

